WAY-213,613: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
Tags: mobile edit mobile web edit
 
CSV import
 
Line 1: Line 1:
'''WAY-213,613''' is a [[drug]] that acts as a potent and selective [[antagonist]] for the [[glutamate receptor]] subtype known as mGluR7. It was developed by the pharmaceutical company [[Wyeth]] and has been used in scientific research to study the role of mGluR7 in the brain.
== WAY-213,613 ==


==Pharmacology==
[[File:WAY-213,613_structure.png|thumb|right|Chemical structure of WAY-213,613]]
WAY-213,613 is a [[competitive antagonist]], meaning it binds to the same site on the mGluR7 receptor as the natural ligand, [[glutamate]], but does not activate the receptor. This blocks the action of glutamate and reduces the activity of the receptor. The mGluR7 receptor is a member of the [[metabotropic glutamate receptors]] (mGluRs), a family of G protein-coupled receptors that are involved in a variety of physiological processes in the brain, including [[neurotransmission]], [[neuroplasticity]], and [[neuroprotection]].


==Research==
'''WAY-213,613''' is a chemical compound that has been studied for its potential effects on the [[central nervous system]]. It is classified as a selective [[serotonin reuptake inhibitor]] (SSRI) and has been investigated for its potential use in treating [[depression]] and other mood disorders.
Research with WAY-213,613 has provided valuable insights into the role of mGluR7 in the brain. Studies have shown that mGluR7 is involved in the regulation of [[anxiety]] and [[pain perception]], and that antagonists like WAY-213,613 can have anxiolytic and analgesic effects. However, the precise mechanisms by which mGluR7 regulates these processes are still not fully understood, and further research is needed to elucidate them.


==Potential Therapeutic Applications==
=== Chemical Properties ===
Given its effects on anxiety and pain, WAY-213,613 has potential therapeutic applications in the treatment of [[anxiety disorders]] and [[chronic pain]] conditions. However, as of now, it is still in the experimental stage and has not been approved for clinical use. Further research and clinical trials are needed to determine its safety and efficacy in humans.
WAY-213,613 is a small molecule with a specific chemical structure that allows it to interact with the [[serotonin transporter]] (SERT) in the brain. The structure of WAY-213,613 is shown in the image to the right. This interaction inhibits the reuptake of serotonin, thereby increasing its availability in the synaptic cleft and enhancing serotonergic neurotransmission.


==See Also==
=== Mechanism of Action ===
* [[Metabotropic glutamate receptor]]
WAY-213,613 functions primarily by blocking the reuptake of serotonin into the presynaptic neuron. This action is similar to that of other SSRIs, which are commonly used as [[antidepressants]]. By preventing the reuptake of serotonin, WAY-213,613 increases the concentration of serotonin in the synaptic cleft, which can help alleviate symptoms of depression and anxiety.
* [[Glutamate (neurotransmitter)]]
 
* [[Neurotransmission]]
=== Potential Therapeutic Uses ===
* [[Neuroplasticity]]
The primary therapeutic interest in WAY-213,613 lies in its potential to treat [[major depressive disorder]] and other related conditions. SSRIs like WAY-213,613 are often prescribed for their efficacy in improving mood and emotional stability. However, the specific clinical applications of WAY-213,613 are still under investigation, and it has not been approved for clinical use.
* [[Neuroprotection]]
 
* [[Anxiety disorder]]
=== Research and Development ===
* [[Chronic pain]]
Research on WAY-213,613 has primarily been conducted in preclinical settings. Studies have focused on its pharmacokinetics, pharmacodynamics, and potential side effects. The compound's selectivity for the serotonin transporter over other monoamine transporters is a key area of interest, as it may influence its side effect profile and therapeutic efficacy.
 
=== Side Effects ===
As with other SSRIs, potential side effects of WAY-213,613 may include [[nausea]], [[insomnia]], [[sexual dysfunction]], and [[weight gain]]. The exact side effect profile of WAY-213,613 is not fully characterized, as it has not undergone extensive clinical trials.
 
== Related Pages ==
* [[Selective serotonin reuptake inhibitor]]
* [[Serotonin]]
* [[Depression (mood disorder)]]
* [[Pharmacology]]


[[Category:Drugs]]
[[Category:Pharmacology]]
[[Category:Pharmacology]]
[[Category:Neuroscience]]
[[Category:Serotonin reuptake inhibitors]]
[[Category:Anxiety]]
[[Category:Pain]]
{{Pharmacology-stub}}
{{Neuroscience-stub}}
{{Anxiety-stub}}
{{Pain-stub}}

Latest revision as of 11:42, 15 February 2025

WAY-213,613[edit]

Chemical structure of WAY-213,613

WAY-213,613 is a chemical compound that has been studied for its potential effects on the central nervous system. It is classified as a selective serotonin reuptake inhibitor (SSRI) and has been investigated for its potential use in treating depression and other mood disorders.

Chemical Properties[edit]

WAY-213,613 is a small molecule with a specific chemical structure that allows it to interact with the serotonin transporter (SERT) in the brain. The structure of WAY-213,613 is shown in the image to the right. This interaction inhibits the reuptake of serotonin, thereby increasing its availability in the synaptic cleft and enhancing serotonergic neurotransmission.

Mechanism of Action[edit]

WAY-213,613 functions primarily by blocking the reuptake of serotonin into the presynaptic neuron. This action is similar to that of other SSRIs, which are commonly used as antidepressants. By preventing the reuptake of serotonin, WAY-213,613 increases the concentration of serotonin in the synaptic cleft, which can help alleviate symptoms of depression and anxiety.

Potential Therapeutic Uses[edit]

The primary therapeutic interest in WAY-213,613 lies in its potential to treat major depressive disorder and other related conditions. SSRIs like WAY-213,613 are often prescribed for their efficacy in improving mood and emotional stability. However, the specific clinical applications of WAY-213,613 are still under investigation, and it has not been approved for clinical use.

Research and Development[edit]

Research on WAY-213,613 has primarily been conducted in preclinical settings. Studies have focused on its pharmacokinetics, pharmacodynamics, and potential side effects. The compound's selectivity for the serotonin transporter over other monoamine transporters is a key area of interest, as it may influence its side effect profile and therapeutic efficacy.

Side Effects[edit]

As with other SSRIs, potential side effects of WAY-213,613 may include nausea, insomnia, sexual dysfunction, and weight gain. The exact side effect profile of WAY-213,613 is not fully characterized, as it has not undergone extensive clinical trials.

Related Pages[edit]

Retrieved from "https://wikimd.com/index.php?title=WAY-213,613&oldid=6296824"